Raras
Buscar doenças, sintomas, genes...
Síndrome Alport ligada ao X
ORPHA:88917CID-10 · Q87.8CID-11 · LD2H.YOMIM 301050DOENÇA RARA

Forma ligada ao X da síndrome de Alport.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Forma ligada ao X da síndrome de Alport.

Pesquisas ativas
2 ensaios
3 total registrados no ClinicalTrials.gov
Publicações científicas
321 artigos
Último publicado: 2026 Apr
Medicamentos
4 registrados
HYDROXYCHLOROQUINE, BENAZEPRIL, HYDROXYCHLOROQUINE SULFATE

Tem tratamento?

4 medicamentos registrados
Ver detalhes, fases e interações →
HYDROXYCHLOROQUINEBENAZEPRILHYDROXYCHLOROQUINE SULFATEBENAZEPRIL HYDROCHLORIDE

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
Childhood
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: Q87.8
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (5)
0202010503
Cariótipo — bandas G, Q ou Rgenetic_test
0202010600
Pesquisa de microdeleções/microduplicações por FISHlab_test
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202010260
Dosagem de alfa-fetoproteína
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫘
Rins
7 sintomas
👁️
Olhos
2 sintomas
📏
Crescimento
1 sintomas
👂
Ouvidos
1 sintomas
🧠
Neurológico
1 sintomas
🩸
Sangue
1 sintomas

+ 9 sintomas em outras categorias

Características mais comuns

88%prev.
Coloração reduzida da cadeia alfa 5 de colágeno IV epidérmico
Frequência: 183/207
Proteinúria
Hipoparatireoidismo
Deficiência auditiva neurossensorial
Hematúria microscópica
Leiomiomatose difusa
23sintomas
Muito frequente (1)
Sem dados (22)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 23 características clínicas mais associadas, ordenadas por frequência.

Coloração reduzida da cadeia alfa 5 de colágeno IV epidérmicoReduced epidermal collagen IV alpha 5 chain staining
Frequência: 183/20788%
ProteinúriaProteinuria
HipoparatireoidismoHypoparathyroidism
Deficiência auditiva neurossensorialSensorineural hearing impairment
Hematúria microscópicaMicroscopic hematuria

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico321PubMed
Últimos 10 anos164publicações
Pico202022 papers
Linha do tempo
2026Hoje · 2026🧪 2007Primeiro ensaio clínico📈 2020Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

3 genes identificados com associação a esta condição. Padrão de herança: X-linked dominant.

COL4A5Collagen alpha-5(IV) chainDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (2)
Collagen biosynthesis and modifying enzymesCollagen chain trimerization
MECANISMO DE DOENÇA

Alport syndrome 1, X-linked

A syndrome that is characterized by progressive glomerulonephritis, renal failure, sensorineural deafness, specific eye abnormalities (lenticonous and macular flecks), and glomerular basement membrane defects. The disorder shows considerable heterogeneity in that families differ in the age of end-stage renal disease and the occurrence of deafness.

OUTRAS DOENÇAS (3)
X-linked Alport syndromedigenic Alport syndromeX-linked diffuse leiomyomatosis-Alport syndrome
HGNC:2207UniProt:P29400
COL4A3Collagen alpha-3(IV) chainMENDELIANTolerante
FUNÇÃO

Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen Tumstatin, a cleavage fragment corresponding to the collagen alpha 3(IV) NC1 domain, possesses both anti-angiogenic and anti-tumor cell activity; these two anti-tumor properties may be regulated via RGD-independent ITGB3-mediated mechanisms

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (1)
Collagen degradation
OUTRAS DOENÇAS (6)
hematuria, benign familial, 2Alport syndrome 3b, autosomal recessiveautosomal dominant Alport syndromeautosomal recessive Alport syndrome
HGNC:2204UniProt:Q01955
COL4A4Collagen alpha-4(IV) chainMENDELIANTolerante
FUNÇÃO

Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (2)
Collagen biosynthesis and modifying enzymesCollagen chain trimerization
MECANISMO DE DOENÇA

Alport syndrome 2, autosomal recessive

A syndrome characterized by progressive glomerulonephritis, glomerular basement membrane defects, renal failure, sensorineural deafness and specific eye abnormalities (lenticonous and macular flecks). The disorder shows considerable heterogeneity in that families differ in the age of end-stage renal disease and the occurrence of deafness.

OUTRAS DOENÇAS (4)
hematuria, benign familial, 1autosomal recessive Alport syndromedigenic Alport syndromeautosomal dominant Alport syndrome
HGNC:2206UniProt:P53420

Medicamentos e terapias

HYDROXYCHLOROQUINEPhase 2

Mecanismo: Toll-like receptor 7 antagonist

BENAZEPRILPhase 2

Mecanismo: Angiotensin-converting enzyme inhibitor

HYDROXYCHLOROQUINE SULFATEPhase 2

Mecanismo: Toll-like receptor 7 antagonist

BENAZEPRIL HYDROCHLORIDEPhase 2

Mecanismo: Angiotensin-converting enzyme inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

1,742 variantes patogênicas registradas no ClinVar.

🧬 COL4A5: NM_033380.3(COL4A5):c.3713G>T (p.Gly1238Val) ()
🧬 COL4A5: NM_033380.3(COL4A5):c.3169G>A (p.Gly1057Arg) ()
🧬 COL4A5: NM_033380.3(COL4A5):c.3089G>T (p.Gly1030Val) ()
🧬 COL4A5: NM_033380.3(COL4A5):c.2059G>A (p.Gly687Arg) ()
🧬 COL4A5: NM_033380.3(COL4A5):c.2059G>T (p.Gly687Trp) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1,276 variantes classificadas pelo ClinVar.

447
829
Patogênica (35.0%)
VUS (65.0%)
VARIANTES MAIS SIGNIFICATIVAS
COL4A5: NM_033380.3(COL4A5):c.1587+6T>G [Pathogenic]
COL4A5: NM_033380.3(COL4A5):c.3722G>C (p.Gly1241Ala) [Likely pathogenic]
COL4A5: NM_033380.3(COL4A5):c.3839del (p.Leu1280fs) [Likely pathogenic]
COL4A5: NM_033380.3(COL4A5):c.2717del (p.Pro906fs) [Likely pathogenic]
COL4A5: NM_033380.3(COL4A5):c.1109_1113del (p.Lys370fs) [Likely pathogenic]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 26
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 4 medicamentos · 3 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome Alport ligada ao X

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

3 ensaios clínicos encontrados, 2 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
168 papers (10 anos)
#1

Systematic reassessment of reported variants in individuals with suspicion of Alport spectrum disorder reveals a high rate of ambiguous results.

European journal of human genetics : EJHG2026 Mar 18

"Alport spectrum disorder" describes a phenotypically and genotypically multifaceted disease entity encompassing classic autosomal recessive and X-linked Alport syndrome (AS) but also more heterogenous and typically milder, yet not benign, hematuric phenotypes like autosomal dominant AS, formerly also known as thin basement membrane nephropathy (TBMN). Alport spectrum disorder is associated with disease-causing variants in the type IV collagen genes COL4A3, COL4A4 and COL4A5. Variants and genotypes, reported by a genetic diagnostics lab between 2009 and 2014, of 91 index cases with the clinical tentative diagnosis of AS (66/91), TBMN (21/91), or AS/TBMN (not specified further; 4/91), were reassessed based on 2015 ACMG (American College of Medical Genetics and Genomics) criteria and current amendments. 80 different variants, all originally reported as "mutations", and their genotypes have been reassessed (COL4A3: 21/80, COL4A4: 15/80, COL4A5: 44/80). In 10/80 variants, classification changed from disease-causing to variant of uncertain significance (VUS). 69/91 (76%) index cases included in the analysis could be classified as solved. 22/91 (24%) index cases had an ambiguous result either on variant, genotype, or both variant and genotype level. VUS cases had a significantly more limited phenotype (e.g., isolated microscopic hematuria) compared to non-downgraded cases (e.g., additional extrarenal manifestations). Reassessment of variants/genotypes in this study showed a significant reduction in unequivocal genetic diagnoses highlighting variant and genotype interpretation as a dynamic process. Genetic reports of individuals with suspected Alport spectrum disorder, especially those obtained in the pre-ACMG criteria era, should therefore be critically evaluated.

#2

Heterozygous X-linked Alport syndrome in a pregnant woman: A case report.

SAGE open medical case reports2026

Alport syndrome is a genetic disorder of chronic kidney disease, hearing loss, and ocular abnormalities, caused by mutations in type IV collagen. While X-linked Alport Syndrome demonstrates characteristic severe renal failure in males, it has a variable presentation in females. Here, we present a case of a pregnant woman who was found to have X-linked Alport Syndrome with a heterozygous c.3587G>A (p.Gly1196Glu) mutation in the COL4A5 gene. The patient presented in her third trimester of pregnancy with preexisting chronic proteinuria. Family history was notable for kidney failure in her mother and two brothers, consistent with suspected hereditary nephropathy. She developed worsening proteinuria and new-onset hematuria, without preeclampsia or renal failure, and was induced at 39 weeks with an uncomplicated delivery. Genetic testing revealed a heterozygous c.3587G>A (p.Gly1196Glu) mutation in the COL4A5 gene, consistent with X-linked Alport Syndrome. Postpartum, the patient had mildly worsened proteinuria that transiently reached nephrotic range before improving, with normal to low blood pressures. Out of concern for symptomatic hypotension, she was not a candidate for first-line therapy with renin-angiotensin-aldosterone system blockade. In cases of hereditary nephropathies such as X-linked Alport Syndrome, cascade testing may be highly considered to identify family members at risk. Our case demonstrates the variable phenotype of X-linked Alport Syndrome in females and the need for close management during pregnancy, along with the benefits of early genetic testing, given the risks of long-term renal, hearing, and ocular manifestations of this disease.

#3

The Inheritance Puzzle: A Case of Dual Genetic Kidney Disease.

Nephrology (Carlton, Vic.)2026 Mar

Autosomal Dominant Polycystic Kidney Disease (ADPKD) and X-Linked Alport Syndrome (AS) are the most common monogenic causes of chronic kidney disease (CKD), each capable of independently leading to end-stage kidney disease (ESKD). However, the concurrent presence of both disorders in a single individual is exceedingly rare and poses significant diagnostic complexity. We report a unique case involving dual diagnosis of ADPKD and AS, attributed to a paternal PKD1 variant and a maternally inherited COL4A5 variant. Initial genetic testing through next-generation sequencing (NGS) identified PKD1 and COL4A5 variants in the Proband. While Sanger sequencing confirmed the PKD1 variant in the father, Sanger analysis of the Mother did not detect the COL4A5 variant despite her clinical signs, including persistent microhematuria and basement membrane abnormalities on electron microscopy. Further investigation using high-sensitivity approaches, like customised amplicon-based deep sequencing, confirmed low-level mosaicism for the COL4A5 variant in the Mother. This case underscores the critical role of advanced genetic testing in resolving atypical or dual presentations of kidney disease and highlights the need to consider mosaicism in unexplained inheritance patterns. Comprehensive family evaluation and precision diagnostics are essential for accurate counselling and management in such complex cases. This report contributes to the expanding spectrum of dual monogenic kidney disease.

#4

Hereditary Myopathy With Early Respiratory Failure Associated With an Incidental COL4A5 Variant: A Case Report.

Case reports in genetics2026

Hereditary myopathy with early respiratory failure (HMERF) is a rare autosomal dominant disorder caused by TTN variants. COL4A5 mutations are linked to X-linked Alport syndrome. A 34-year-old male developed progressive lower limb weakness, gait disturbance, nocturnal hypoventilation, and calf hypertrophy. Family history revealed similar symptoms in his mother and sister. Examination showed absent reflexes; MRI demonstrated muscle atrophy and fatty replacement; needle electromyography (EMG) was performed and showed findings consistent with advanced myopathy; however, it was not used as a primary diagnostic tool. Whole-exome sequencing identified a pathogenic TTN variant (c.95126C > G, p.Pro31709Arg), confirming HMERF. A hemizygous COL4A5 variant (c.4891C > T, p.Arg1631Cys) was also detected but lacked clinical correlation. This case illustrates a classic HMERF phenotype confirmed genetically, with an incidental COL4A5 variant of uncertain significance. It underscores the importance of genomic testing in atypical neuromuscular presentations and the need for cautious interpretation of incidental findings.

#5

mRNA Therapy for Alport Syndrome.

bioRxiv : the preprint server for biology2026 Jan 21

Alport syndrome is caused by mutations in the type IV collagen genes COL4A3, COL4A4, and COL4A5 which are expressed in podocytes in the glomerulus of the kidney. Mutation of these genes disrupts blood filtration by the kidney leading to proteinuria and kidney failure. There is no cure for Alport Syndrome. Current therapies do not treat the genetic cause of the disease, but instead aim to delay the disease by reducing blood pressure in the kidney. Here we tested the ability of mRNA therapy to treat the disease. Mice with X-linked Alport syndrome (XLAS) due to mutation of Col4A5 were treated intravenously with lipid nanoparticles (LNPs) carrying three mRNAs encoding COL4A3, COL4A4, and COL4A5 to produce trimeric collagen IV repair proteins. This intravenous mRNA therapy significantly reduced proteinuria and blood urea nitrogen. Protection against the syndrome was maintained provided that LNP-mRNA injections were continued. However, efficacy was lost when therapy was terminated. These data provide proof of principle to apply a genetic mRNA therapy to halt progression of Alport syndrome in a mouse model of XLAS. These data also demonstrate that damage to the kidney filtration barrier can be leveraged to deliver large molecular therapies to podocytes and other cells within the kidney to treat Alport syndrome and other kidney genetic diseases.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC165 artigos no totalmostrando 164

2026

Systematic reassessment of reported variants in individuals with suspicion of Alport spectrum disorder reveals a high rate of ambiguous results.

European journal of human genetics : EJHG
2026

Heterozygous X-linked Alport syndrome in a pregnant woman: A case report.

SAGE open medical case reports
2026

The Inheritance Puzzle: A Case of Dual Genetic Kidney Disease.

Nephrology (Carlton, Vic.)
2026

Hereditary Myopathy With Early Respiratory Failure Associated With an Incidental COL4A5 Variant: A Case Report.

Case reports in genetics
2026

mRNA Therapy for Alport Syndrome.

bioRxiv : the preprint server for biology
2026

Whole-genome sequencing identified a deep intronic COL4A5 variant causing aberrant splicing in a female patient with X-linked Alport syndrome.

CEN case reports
2025

Anticodon-edited tRNA enables translational readthrough of COL4A5 premature termination codons.

PloS one
2026

Splice modulation of COL4A5 reinstates collagen IV assembly in an organoid model of Alport syndrome.

JCI insight
2026

Investigation of clinical and genetic characteristics of Alport syndrome using a national registry in Japan (JP-ALPS).

Clinical and experimental nephrology
2025

A rare case of dual glomerular pathology: Alport syndrome and immune complex-mediated MPGN.

BMC nephrology
2025

Case Report: Whole genome sequencing identifies a novel deep intronic COL4A5 variant of uncertain significance in X-linked Alport syndrome.

Frontiers in pediatrics
2025

Unveiling Maternal Germline Mosaicism in X-Linked Alport Syndrome by Advanced Genetic Testing.

The American journal of case reports
2025

A Prediction Model of Disease Progression in X-Linked Alport syndrome Based on Clinical Characteristics and Genetic Variants.

Kidney international reports
2025

A comprehensive splicing characterization of COL4A5 mutations and prognostic significance in a single cohort with X-linked alport syndrome.

Frontiers in genetics
2025

A retrospective study of kidney disease in Alport syndrome during and after pregnancy.

Journal of nephrology
2025

A novel mouse model for X-linked Alport syndrome induced by splicing mutation in the Col4a5 gene.

Scientific reports
2025

[New Genetic Variants Involved in the Pathogenesis of Autosomal Dominant Alport Syndrome: A Familial Case Report].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
2025

Clinical differences between female monozygotic twins with X-linked Alport syndrome with somatic mosaicism.

Pediatric nephrology (Berlin, Germany)
2025

Increased HA/CD44/TGFβ signaling implicates in renal fibrosis of a Col4a5 mutant Alport mice.

Molecular medicine (Cambridge, Mass.)
2025

Corneal endothelial neovascularization and glaucoma in X-linked Alport syndrome.

European journal of ophthalmology
2025

Genotype-Based Molecular Mechanisms in Alport Syndrome.

Journal of the American Society of Nephrology : JASN
2025

Alport syndrome: an update.

Current opinion in nephrology and hypertension
2025

Genotype-First Analysis in an Unselected Health System-Based Population and Phenotypic Severity of COL4A5 Variants.

Journal of the American Society of Nephrology : JASN
2024

Natural History of Auditory Function in Patients with Alport Syndrome: A Case Series Study.

Journal of clinical medicine
2025

Renal transplantation in Alport syndrome.

Kidney research and clinical practice
2025

A Novel Deep Learning Approach for Analyzing Glomerular Basement Membrane Lesions in a Mouse Model of X-Linked Alport Syndrome.

The American journal of pathology
2024

Analyzing three pedigrees in X-linked Alport syndrome with the presentation of nephrotic syndrome.

Frontiers in genetics
2025

Genotype and X-chromosome inactivation are associated with disease severity in females with X-linked Alport syndrome.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
2024

Establishment of an induced pluripotent stem cell line from a patient with X-linked Alport syndrome carrying a hemizygous splicing variant (NM_033380; c.929[exon 16]delG) in the collagen type IV alpha 5 chain gene.

Stem cell research
2024

Genotype-first analysis in an unselected health system-based population reveals variable phenotypic severity of COL4A5 variants.

medRxiv : the preprint server for health sciences
2024

Aberrant Splicing of COL4A5 Intronic Variant Contribute to the Pathogenesis of X-Linked Alport Syndrome: A Case Series.

International journal of nephrology and renovascular disease
2024

An unusual case of nephrotic syndrome.

Pediatric nephrology (Berlin, Germany)
2024

Staircase Lamellar Macular Hole in a Male Patient Aged 54 Years.

JAMA ophthalmology
2024

X-linked Alport syndrome presenting in mother and son with the same unique histopathological features.

Journal of nephrology
2024

Trimerization profile of type IV collagen COL4A5 exon deletion in X-linked Alport syndrome.

Clinical and experimental nephrology
2024

Three exonic variants in the COL4A5 gene alter RNA splicing in a minigene assay.

Molecular genetics &amp; genomic medicine
2024

[A case of X-linked Alport syndrome with esophageal leiomyomatosis].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2024

Genetic, Clinical, and Pathologic Backgrounds of Children With X-Linked Alport Syndrome in China: A Monocenter Study.

Global pediatric health
2024

Novel Digenic Variants in COL4A4 and COL4A5 Causing X-Linked Alport Syndrome: A Case Report.

Case reports in nephrology and dialysis
2023

High-flow arteriovenous fistula in X-linked Alport syndrome: a case report.

Frontiers in medicine
2023

Sporadic Case of Heterozygous X-Linked Alport Syndrome.

Glomerular diseases
2023

Case report: Preimplantation genetic testing for X-linked alport syndrome caused by variation in the COL4A5 gene.

Frontiers in pediatrics
2023

A comparison of the ocular features in Pierson and Alport syndrome: a case report and literature review.

Ophthalmic genetics
2023

X-linked Alport Syndrome with Type IV Collagen α5 Chain Staining Revealing Normal Expression in the Glomerular Basement Membrane and Negative on Bowman's Capsule and Distal Tubular Basement Membrane: A Case Report.

The Tohoku journal of experimental medicine
2023

The outcomes of renin-angiotensin-aldosterone system inhibition and immunosuppressive therapy in children with X-linked Alport syndrome.

The Turkish journal of pediatrics
2023

A wave of deep intronic mutations in X-linked Alport syndrome.

Kidney international
2023

Genetic features and kidney morphological changes in women with X-linked Alport syndrome.

Journal of medical genetics
2023

Electroretinographic abnormalities in Alport syndrome with a novel COL4A5 truncated variant (p.Try20GlyfsTer19).

Documenta ophthalmologica. Advances in ophthalmology
2023

Alport Syndrome: Clinical Spectrum and Therapeutic Advances.

Kidney medicine
2023

Genotype-phenotype correlation of X-linked Alport syndrome observed in both genders: a multicenter study in South Korea.

Scientific reports
2023

Clinical, histological and molecular characteristics of Alport syndrome in Chinese children.

Journal of nephrology
2023

A mouse model for X-linked Alport syndrome induced by Del-ATGG in the Col4a5 gene.

Frontiers in medicine
2023

Hydroxychloroquine Ameliorates Hematuria in Children with X-Linked Alport Syndrome: Retrospective Case Series Study.

Pharmacogenomics and personalized medicine
2023

Identification and functional characterization of a novel truncating splicing variant in COL4A5 gene causing X-linked Alport syndrome with astigmatism.

Chinese medical journal
2022

A deep intronic splice variant of the COL4A5 gene in a Chinese family with X-linked Alport syndrome.

Frontiers in pediatrics
2022

Novel and Founder Pathogenic Variants in X-Linked Alport Syndrome Families in Greece.

Genes
2023

Bullous Pemphigoid in X-linked Alport Syndrome.

Internal medicine (Tokyo, Japan)
2022

A Systematic Review of Pathogenic COL4A5 Variants and Proteinuria in Women and Girls With X-linked Alport Syndrome.

Kidney international reports
2023

Aberrant splicing caused by exonic single nucleotide variants positioned 2nd or 3rd to the last nucleotide in the COL4A5 gene.

Clinical and experimental nephrology
2022

Renal X-inactivation in female individuals with X-linked Alport syndrome primarily determined by age.

Frontiers in medicine
2022

A novel COL4A5 splicing variant causing X-linked Alport syndrome: A case report.

Human genome variation
2022

Temporal retinal thinning might be an early diagnostic indicator in male pediatric X-linked Alport syndrome.

International journal of ophthalmology
2022

Pathogenicity of missense variants affecting the collagen IV α5 carboxy non-collagenous domain in X-linked Alport syndrome.

Scientific reports
2022

Identification of 27 Novel Variants in Genes COL4A3, COL4A4, and COL4A5 in Lithuanian Families With Alport Syndrome.

Frontiers in medicine
2022

Identification of Four Novel COL4A5 Variants and Detection of Splicing Abnormalities in Three Chinese X-Linked Alport Syndrome Families.

Frontiers in genetics
2022

Detection of Very Low-Level Somatic Mosaic COL4A5 Splicing Variant in Asymptomatic Female Using Droplet Digital PCR.

Frontiers in medicine
2022

Refractory focal segmental glomerulosclerosis caused by Alport syndrome detected by genetic testing after three decades.

BMJ case reports
2022

The Contribution of COL4A5 Splicing Variants to the Pathogenesis of X-Linked Alport Syndrome.

Frontiers in medicine
2022

Genotype-phenotype correlations for COL4A3-COL4A5 variants resulting in Gly substitutions in Alport syndrome.

Scientific reports
2022

Last Nucleotide Substitutions of COL4A5 Exons Cause Aberrant Splicing.

Kidney international reports
2021

Preimplantation Genetic Testing Prevented Intergenerational Transmission of X-Linked Alport Syndrome.

Kidney diseases (Basel, Switzerland)
2021

Modelling X-linked Alport Syndrome With Induced Pluripotent Stem Cell-Derived Podocytes.

Kidney international reports
2021

Clinical Manifestations of Alport Syndrome-Diffuse Leiomyomatosis Patients With Contiguous Gene Deletions in COL4A6 and COL4A5.

Frontiers in medicine
2021

Publisher Correction: Creation of X-linked Alport syndrome rat model with Col4a5 deficiency.

Scientific reports
2021

Functional assessment of a novel COL4A5 splicing site variant in a Chinese X-linked Alport syndrome family.

Annals of translational medicine
2021

Creation of X-linked Alport syndrome rat model with Col4a5 deficiency.

Scientific reports
2022

Effect of disease progression on the podocyte cell cycle in Alport Syndrome.

Kidney international
2021

Determination of the pathogenicity of a novel COL4A5 missense variant by CRISPR-Cas9 in kidney podocytes.

American journal of translational research
2022

Family History is Important to Identify Patients with Monogenic Causes of Adult-Onset Chronic Kidney Disease.

Nephron
2022

THE SPECTRUM OF INTERNAL LIMITING MEMBRANE DISEASE IN ALPORT SYNDROME: A Multimodal Imaging Study.

Retina (Philadelphia, Pa.)
2021

Generation of a COL4A5 heterozygous mutation human embryonic stem cell line (WAe009-A-58) using an episomal vector-based CRISPR/Cas9 system.

Stem cell research
2021

Generation of an iPSC line (GWCMCi002-A) from an X-linked Alport syndrome patient with a hemizygous splicing mutation (NM_000495.4, c. 1517-1 G > T) in the COL4A5 gene.

Stem cell research
2021

Uncovering Modifier Genes of X-Linked Alport Syndrome Using a Novel Multiparent Mouse Model.

Journal of the American Society of Nephrology : JASN
2021

Mother-Son Kidney Transplantation in Patients With X-Linked Alport Syndrome.

Kidney international reports
2021

Generation of two induced pluripotent stem cell lines from patients with X-linked Alport syndrome.

Stem cell research
2021

Novel Mutations of COL4A5 Identified in Chinese Families with X-Linked Alport Syndrome and Literature Review.

BioMed research international
2022

Population-based studies reveal an additive role of type IV collagen variants in hematuria and albuminuria.

Pediatric nephrology (Berlin, Germany)
2021

Case Report: Preimplantation Genetic Testing and Pregnancy Outcomes in Women With Alport Syndrome.

Frontiers in genetics
2021

Complex Phenotypic Presentation of Syndromic Hearing Loss Deciphered as Three Separate Clinical Entities: How Genetic Testing Guides Final Diagnosis.

Audiology &amp; neuro-otology
2020

X-Linked Alport Syndrome in Women: Genotype and Clinical Course in 24 Cases.

Frontiers in medicine
2021

Mild X-linked Alport syndrome due to the COL4A5 G624D variant originating in the Middle Ages is predominant in Central/East Europe and causes kidney failure in midlife.

Kidney international
2020

Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome.

Kidney research and clinical practice
2020

A novel missense mutation of COL4A5 gene alter collagen IV α5 chain to cause X-linked Alport syndrome in a Chinese family.

Translational pediatrics
2020

Generation of an urine-derived induced pluripotent stem cell line from a 5-year old X-linked Alport syndrome (X-LAS) patient.

Stem cell research
2021

Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020.

Pediatric nephrology (Berlin, Germany)
2020

Bidirectional, non-necrotizing glomerular crescents are the critical pathology in X-linked Alport syndrome mouse model harboring nonsense mutation of human COL4A5.

Scientific reports
2020

[Clinical phenotype of Alport syndrome in monozygotic twins].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2020

New-onset Psychosis in an Immunosuppressed Patient With Kidney Transplantation: An Educational Case Report.

Canadian journal of kidney health and disease
2020

Low frequency of parental mosaicism in de novo COL4A5 mutations in X-linked Alport syndrome.

Molecular genetics &amp; genomic medicine
2019

Glomerular Basement Membrane Protein Expression and the Diagnosis and Prognosis of Autosomal Dominant Alport Syndrome.

Kidney medicine
2020

Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome.

Kidney international
2020

Comparative Functional Analysis in vitro of 2 COL4A5 Splicing Mutations at the Same Site in 2 Unrelated Alport Syndrome Chinese Families.

Cytogenetic and genome research
2020

A case with somatic and germline mosaicism in COL4A5 detected by multiplex ligation-dependent probe amplification in X-linked Alport syndrome.

CEN case reports
2020

Identification of four novel mutations in the COL4A5 gene identified in Chinese patients with X-linked Alport syndrome.

Biomedical reports
2020

Pathogenic evaluation of synonymous COL4A5 variants in X-linked Alport syndrome using a minigene assay.

Molecular genetics &amp; genomic medicine
2020

Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5.

Nature communications
2020

Generation of an induced pluripotent stem cell line (SHCDNRi001-A) from a patient with X-linked Alport syndrome carrying a heterozygous p.G409S (c. 1225 G > A) mutation in the COL4A5 gene.

Stem cell research
2020

Femtosecond laser-assisted cataract surgery for bilateral anterior lenticonus.

Journal of cataract and refractive surgery
2020

The First COL4A5 Exon 41A Glycine Substitution in a Family With Alport Syndrome.

Frontiers in pediatrics
2020

Corneal endothelial cell abnormalities in X-linked Alport syndrome.

Ophthalmic genetics
2020

Endoplasmic Reticulum Stress Activation in Alport Syndrome Varies Between Genotype and Cell Type.

Frontiers in genetics
2020

X-linked Alport syndrome with "empty capsule sign".

Kidney international
2020

Detection of Cryptic Mosaicism in X-linked Alport Syndrome Prompts to Re-evaluate Living-donor Kidney Transplantation.

Transplantation
2019

The Hypomorphic Variant p.(Gly624Asp) in COL4A5 as a Possible Cause for an Unexpected Severe Phenotype in a Family With X-Linked Alport Syndrome.

Frontiers in pediatrics
2020

Reassessing the pathogenicity of c.2858G>T(p.(G953V)) in COL4A5 Gene: report of 19 Chinese families.

European journal of human genetics : EJHG
2019

A COL4A5 Missense Variant in a Han-Chinese Family with X-linked Alport Syndrome.

Current molecular medicine
2019

Determination of the pathogenicity of known COL4A5 intronic variants by in vitro splicing assay.

Scientific reports
2019

[Alport syndrome. Report of two cases].

Revista medica de Chile
2019

Somatic Mosaicism in a Male Patient With X-linked Alport Syndrome.

Kidney international reports
2019

De novo X-linked Alport syndrome in a 3-year-old girl.

BMJ case reports
2019

Identification of a novel COL4A5 mutation in the proband initially diagnosed as IgAN from a Chinese family with X-linked Alport syndrome.

Science China. Life sciences
2019

Novel mutations in patients with X-linked Alport syndrome: Two case reports.

Medicine
2019

Increased microvascular disease in X-linked and autosomal recessive Alport syndrome: a case control cross sectional observational study.

Ophthalmic genetics
2019

A triad of retinal signs in Alport syndrome: The 'stair-case' fovea, choroidal thinning and peripheral schisis.

European journal of ophthalmology
2019

Effect of heterozygous pathogenic COL4A3 or COL4A4 variants on patients with X-linked Alport syndrome.

Molecular genetics &amp; genomic medicine
2019

Establishment of X-linked Alport syndrome model mice with a Col4a5 R471X mutation.

Biochemistry and biophysics reports
2018

X-linked Alport syndrome: pathogenic variant features and further auditory genotype-phenotype correlations in males.

Orphanet journal of rare diseases
2019

A family case of X-linked Alport syndrome patients with a novel variant in COL4A5.

CEN case reports
2018

[X-linked Alport syndrome: auditory pathogenic variant features and further genotype-phenotype correlations in female patients].

Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery
2018

Temporal Bone Histopathology of X-linked Inherited Alport Syndrome.

Laryngoscope investigative otolaryngology
2018

Novel deletion mutation in a Chinese family with X-linked alport syndrome.

International journal of clinical and experimental pathology
2019

A review of clinical characteristics and genetic backgrounds in Alport syndrome.

Clinical and experimental nephrology
2019

Germline mosaicism is a pitfall in the diagnosis of "sporadic" X-linked Alport syndrome.

Journal of nephrology
2018

Detection of Splicing Abnormalities and Genotype-Phenotype Correlation in X-linked Alport Syndrome.

Journal of the American Society of Nephrology : JASN
2017

Speech, language, and hearing function in twins with Alport syndrome: A seven-year retrospective case report.

Journal of otology
2018

COL4A5 and LAMA5 variants co-inherited in familial hematuria: digenic inheritance or genetic modifier effect?

BMC nephrology
2018

The COL4A3 and COL4A4 Digenic Mutations in cis Result in Benign Familial Hematuria in a Large Chinese Family.

Cytogenetic and genome research
2017

Natural History and Genotype-Phenotype Correlation in Female X-Linked Alport Syndrome.

Kidney international reports
2018

Pathogenicity of a Human Laminin β2 Mutation Revealed in Models of Alport Syndrome.

Journal of the American Society of Nephrology : JASN
2018

X-Linked Glomerulopathy Due to COL4A5 Founder Variant.

American journal of kidney diseases : the official journal of the National Kidney Foundation
2018

Temporal retinal thinning and the diagnosis of Alport syndrome and Thin basement membrane nephropathy.

Ophthalmic genetics
2017

Generation of integration-free induced pluripotent stem cell lines derived from two patients with X-linked Alport syndrome (XLAS).

Stem cell research
2017

The Chemical Chaperone, PBA, Reduces ER Stress and Autophagy and Increases Collagen IV α5 Expression in Cultured Fibroblasts From Men With X-Linked Alport Syndrome and Missense Mutations.

Kidney international reports
2017

[Detection of large deletions in X linked Alport syndrome using competitive multiplex fluorescence polymerase chain reaction].

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
2017

ANCA vasculitis in a patient with Alport syndrome: a difficult diagnosis but a treatable disease!

BMC nephrology
2017

Characterization of contiguous gene deletions in COL4A6 and COL4A5 in Alport syndrome-diffuse leiomyomatosis.

Journal of human genetics
2017

Familial hematuria: A review.

Medicina (Kaunas, Lithuania)
2017

Functional assessment of a novel COL4A5 splice region variant and immunostaining of plucked hair follicles as an alternative method of diagnosis in X-linked Alport syndrome.

Pediatric nephrology (Berlin, Germany)
2016

X-Linked Alport Dogs Demonstrate Mesangial Filopodial Invasion of the Capillary Tuft as an Early Event in Glomerular Damage.

PloS one
2016

[Alport syndrome: Hereditary nephropathy associated with mutations in genes coding for type IV collagen chains].

Nephrologie &amp; therapeutique
2017

Female X-linked Alport syndrome with somatic mosaicism.

Clinical and experimental nephrology
2016

A Novel Mutation in a Japanese Family with X-linked Alport Syndrome.

Internal medicine (Tokyo, Japan)
2017

Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations.

Pediatric nephrology (Berlin, Germany)
2016

Alport Syndrome in Women and Girls.

Clinical journal of the American Society of Nephrology : CJASN
2016

Genetic, Clinical, and Pathologic Backgrounds of Patients with Autosomal Dominant Alport Syndrome.

Clinical journal of the American Society of Nephrology : CJASN
2016

A Novel Splicing Mutation Identified in a Chinese Family with X-linked Alport Syndrome Using Targeted Next-Generation Sequencing.

Genetic testing and molecular biomarkers
2016

[Clinical and genetic features of X-linked Alport syndrome in men positive for the collagen Ⅳ α5 chain in epidermal basement membrane].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2016

X-linked Alport syndrome associated with a synonymous p.Gly292Gly mutation alters the splicing donor site of the type IV collagen alpha chain 5 gene.

Clinical and experimental nephrology
2015

[Diagnosis of Alport syndrome].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
2015

Phenotypic heterogeneity in females with X-linked Alport syndrome.

Clinical nephrology
2015

Carriers of Autosomal Recessive Alport Syndrome with Thin Basement Membrane Nephropathy Presenting as Focal Segmental Glomerulosclerosis in Later Life.

Nephron
2015

A Novel Mutation in a Kazakh Family with X-Linked Alport Syndrome.

PloS one
2016

Somatic mosaicism and variant frequency detected by next-generation sequencing in X-linked Alport syndrome.

European journal of human genetics : EJHG
2015

Coinheritance of COL4A5 and MYO1E mutations accentuate the severity of kidney disease.

Pediatric nephrology (Berlin, Germany)
Ver todos os 165 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome Alport ligada ao X.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome Alport ligada ao X

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Systematic reassessment of reported variants in individuals with suspicion of Alport spectrum disorder reveals a high rate of ambiguous results.
    European journal of human genetics : EJHG· 2026· PMID 41851263mais citado
  2. Heterozygous X-linked Alport syndrome in a pregnant woman: A case report.
    SAGE open medical case reports· 2026· PMID 41799611mais citado
  3. The Inheritance Puzzle: A Case of Dual Genetic Kidney Disease.
    Nephrology (Carlton, Vic.)· 2026· PMID 41765374mais citado
  4. Hereditary Myopathy With Early Respiratory Failure Associated With an Incidental COL4A5 Variant: A Case Report.
    Case reports in genetics· 2026· PMID 41684416mais citado
  5. mRNA Therapy for Alport Syndrome.
    bioRxiv : the preprint server for biology· 2026· PMID 41648584mais citado
  6. Unusual Glomerular Abnormalities in a Patient With Combined COL4A5-NPHS1 Variants.
    Kidney Med· 2026· PMID 41971232recente
  7. Umbilical cord-derived mesenchymal stem cells restore renal homeostasis in Alport Syndrome: Mechanistic insights and clinical translation.
    J Adv Res· 2026· PMID 41951047recente
  8. NBL1 Associates with Renal Phenotypes in Mice, but Partial Nbl1 Reduction Does Not Ameliorate Kidney Disease.
    Am J Physiol Renal Physiol· 2026· PMID 41910154recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:88917(Orphanet)
  2. OMIM OMIM:301050(OMIM)
  3. MONDO:0010520(MONDO)
  4. GARD:16774(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q27677597(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome Alport ligada ao X
Compêndio · Raras BR

Síndrome Alport ligada ao X

ORPHA:88917 · MONDO:0010520
Prevalência
1-9 / 100 000
Herança
X-linked dominant
CID-10
Q87.8 · Outras síndromes com malformações congênitas especificadas, não classificadas em outra parte
CID-11
Ensaios
2 ativos
Medicamentos
4 registrados
Início
Childhood
Prevalência
0.0 (Europe)
MedGen
UMLS
C1567742
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades